DIAGNOS Inc.
TSX VENTURE : ADK

DIAGNOS Inc.

August 26, 2014 11:05 ET

DIAGNOS Announces First Retinopathy Screening Unit in Eastern Europe

BROSSARD, QUEBEC--(Marketwired - Aug. 26, 2014) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Eastern Europe.

"After running successful screening programs for the same client in both the UAE and India, we are starting our first screening project in Eastern Europe. We are excited to have the opportunity to prove that our screening programs are flexible enough to succeed in any environment, be it rural India or metropolitan Europe. Being our first project in the region, this project will be used as a launch pad for Eastern Europe," said André Larente, Diagnos' President.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection critical to helping prevent vision loss.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.

Contact Information

  • Andre Larente
    President, DIAGNOS Inc.
    (450) 678-8882 ext 224